{"transactions":[{"id":731921,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:01:10.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":39715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":39715,"derivative":{"exercise_price":5.67,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":39715},"source":{"system":"sec-edgar","filing":"0001620152-26-000005","document":"wk-form4_1781812867.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162015226000005/wk-form4_1781812867.xml","form_type":"4"}},{"id":731920,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:01:10.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":26455,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."}],"balance_after":68006,"source":{"system":"sec-edgar","filing":"0001620152-26-000005","document":"wk-form4_1781812867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162015226000005/wk-form4_1781812867.xml","form_type":"4"}},{"id":763906,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T00:03:27.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":123397,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":123397,"derivative":{"exercise_price":4.79,"expiration_date":"2036-05-20","underlying":"Class A Common Stock","underlying_shares":123397},"source":{"system":"sec-edgar","filing":"0001620152-26-000003","document":"form4-05272026_120523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000162015226000003/form4-05272026_120523.xml","form_type":"4"}},{"id":962855,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30932,"price":0.4041,"value":12499.6212,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":30932,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":30932},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962854,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":30932,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the \"Note Exchange Unregistered Pre-Funded Warrants\") to purchase up to 30,932 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 32,191 ADSs (the \"Note Exchange Unregistered Warrants\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised."}],"balance_after":30932,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":30932},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962853,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants to purchase ADRs","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":123731,"price":0.4041,"value":49999.6971,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Conversion Exercise Price of Security is $0.00001"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":123731,"derivative":{"exercise_price":0,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":123731},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":962852,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants to purchase American Depositary Shares (\"ADRs\")","published_at":"2025-12-19T02:56:12.000Z","date":"2025-12-16","kind":"purchase","planned":false,"acquired":true,"shares":123731,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 123,731 ADSs (the \"PIPE PFWs\" and ) and (ii) accompanying Series G Warrants to purchase up to 123,731 ADSs (the \"Series G Warrants\"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised."}],"balance_after":123731,"derivative":{"exercise_price":0.3883,"underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":123731},"source":{"system":"sec-edgar","filing":"0001493152-25-028416","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000149315225028416/ownership.xml","form_type":"4"}},{"id":1103640,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T00:44:06.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":54059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":54059,"derivative":{"exercise_price":3.61,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":54059},"source":{"system":"sec-edgar","filing":"0001628280-25-032730","document":"wk-form4_1750725839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032730/wk-form4_1750725839.xml","form_type":"4"}},{"id":1103639,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T00:44:06.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":41551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock units (\"RSUs\"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.  The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program."}],"balance_after":41551,"source":{"system":"sec-edgar","filing":"0001628280-25-032730","document":"wk-form4_1750725839.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828025032730/wk-form4_1750725839.xml","form_type":"4"}},{"id":1135474,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T20:05:11.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":292983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2025); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":292983,"derivative":{"exercise_price":2.03,"expiration_date":"2035-05-20","underlying":"Class A Common Stock","underlying_shares":292983},"source":{"system":"sec-edgar","filing":"0001415889-25-014416","document":"form4-05232025_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588925014416/form4-05232025_040501.xml","form_type":"4"}},{"id":1193160,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:15.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":225000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0000950170-25-043939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043939/ownership.xml","form_type":"4"}},{"id":1193159,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-24T21:00:15.000Z","date":"2025-03-20","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":175000,"derivative":{"exercise_price":1.5,"expiration_date":"2035-03-20","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-25-043939","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025043939/ownership.xml","form_type":"4"}},{"id":1214563,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrants (Right to Buy)","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2030-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1214562,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrants (Right to Buy)","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."}],"balance_after":44642,"derivative":{"exercise_price":0.87,"exercise_date":"2025-03-06","expiration_date":"2026-03-06","underlying":"American Depositary Shares representing Ordinary Shares","underlying_shares":44642},"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1214561,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2025-03-10T21:00:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":44642,"price":1.12,"value":49999.04,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, the Reporting Person acquired 44,642 ADS  and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant."}],"balance_after":44642,"source":{"system":"sec-edgar","filing":"0000950170-25-036482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017025036482/ownership.xml","form_type":"4"}},{"id":1403258,"issuer":{"id":7692,"kind":"organization","name":"Akari Therapeutics Plc","symbol":"AKTX"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-18T20:40:20.000Z","date":"2024-09-17","kind":"grant","planned":false,"acquired":true,"shares":5000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The stock options have an exercise price of $0.001655 per ordinary share, par value $0.0001 per share (\"Ordinary Share\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. The stock option vests and becomes exercisable ratably in three equal installments with the first installment vesting on the date of the first Annual General Meeting (\"AGM\") following the date of the grant, and with the second and third installments vesting, respectively, on the dates of the second and third AGM's following the date of the grant, subject to the non-employee director's continued service with the Issuer."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares."}],"balance_after":5000000,"derivative":{"exercise_price":0.0017,"expiration_date":"2034-09-17","underlying":"Ordinary Shares, par value $0.0001 per share","underlying_shares":5000000},"source":{"system":"sec-edgar","filing":"0000950170-24-107828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024107828/ownership.xml","form_type":"4"}},{"id":1414060,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-05T21:55:54.000Z","date":"2024-09-03","kind":"grant","planned":false,"acquired":true,"shares":200801,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (September 3, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":200801,"derivative":{"exercise_price":2.98,"expiration_date":"2034-09-02","underlying":"Class A Common Stock","underlying_shares":200801},"source":{"system":"sec-edgar","filing":"0001415889-24-022965","document":"form4-09052024_090950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000141588924022965/form4-09052024_090950.xml","form_type":"4"}},{"id":1477189,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:48:55.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":40243,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":40243,"derivative":{"exercise_price":6.35,"expiration_date":"2034-06-14","underlying":"Common Stock","underlying_shares":40243},"source":{"system":"sec-edgar","filing":"0001628280-24-028596","document":"wk-form4_1718664529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828024028596/wk-form4_1718664529.xml","form_type":"4"}},{"id":1851961,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T22:28:27.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":49237,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":49237,"derivative":{"exercise_price":3.92,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":49237},"source":{"system":"sec-edgar","filing":"0001628280-23-022552","document":"wk-form4_1686954498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023022552/wk-form4_1686954498.xml","form_type":"4"}},{"id":1889253,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-17T21:04:20.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":366744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":366744,"derivative":{"exercise_price":1.64,"expiration_date":"2033-05-14","underlying":"Class A Common Stock","underlying_shares":366744},"source":{"system":"sec-edgar","filing":"0001209191-23-030259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919123030259/doc4.xml","form_type":"4"}},{"id":2220247,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T23:07:44.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":140713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":140713,"derivative":{"exercise_price":4.05,"expiration_date":"2032-05-15","underlying":"Class A Common Stock","underlying_shares":140713},"source":{"system":"sec-edgar","filing":"0001209191-22-039676","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919122039676/doc4a.xml","form_type":"4/A","original_submission_date":"2022-05-18"}},{"id":2227513,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:23:06.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.548,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-22-013087","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761922013087/doc1.xml","form_type":"4"}},{"id":2265883,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-18T20:57:32.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":118784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":118784,"derivative":{"exercise_price":4.05,"expiration_date":"2032-05-15","underlying":"Class A Common Stock","underlying_shares":118784},"source":{"system":"sec-edgar","filing":"0001209191-22-030091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919122030091/doc4.xml","form_type":"4"}},{"id":2529111,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-03T01:29:04.000Z","date":"2021-10-29","kind":"grant","acquired":true,"shares":45229,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date."}],"balance_after":45229,"derivative":{"exercise_price":9.17,"expiration_date":"2031-10-28","underlying":"Class A Common Stock","underlying_shares":45229},"source":{"system":"sec-edgar","filing":"0001209191-21-062585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121062585/doc4.xml","form_type":"4"}},{"id":2660784,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T20:10:42.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":32765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":32765,"derivative":{"exercise_price":7.31,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":32765},"source":{"system":"sec-edgar","filing":"0001567619-21-012430","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761921012430/doc1.xml","form_type":"4"}},{"id":2764528,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-01T21:16:58.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":5000,"price":9.9799,"value":49899.5,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-21-024159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121024159/doc4.xml","form_type":"4"}},{"id":2769057,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2021-03-29T16:30:13.000Z","date":"2021-03-25","kind":"sale","acquired":false,"shares":10328,"price":7.85,"value":81074.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on March 24, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person acquired 977 shares of common stock under the Issuer's 2013 Employee Stock Purchase Plan on February 28, 2021."}],"balance_after":322626,"source":{"system":"sec-edgar","filing":"0000899243-21-013804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924321013804/doc4.xml","form_type":"4"}},{"id":2863796,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:53:30.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":187658,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Received in exchange for an option to purchase 187,392 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vest in 48 equal monthly installments from July 22, 2020."}],"balance_after":187658,"derivative":{"exercise_price":1.74,"expiration_date":"2030-07-21","underlying":"Class A Common Stock","underlying_shares":187658},"source":{"system":"sec-edgar","filing":"0001209191-21-010354","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010354/doc4.xml","form_type":"4"}},{"id":2863795,"issuer":{"id":4384,"kind":"organization","name":"Nuvation Bio Inc."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T22:53:30.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":51703,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. (\"Panacea\") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea (\"Merger Sub\"), and Nuvation Bio Inc. (\"Legacy Nuvation\") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the \"Issuer\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for an option to purchase 51,630 shares of Legacy Nuvation Class A Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest in 48 equal monthly installments from October 5, 2020."}],"balance_after":51703,"derivative":{"exercise_price":4.6,"expiration_date":"2030-10-04","underlying":"Class A Common Stock","underlying_shares":51703},"source":{"system":"sec-edgar","filing":"0001209191-21-010354","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1811063/000120919121010354/doc4.xml","form_type":"4"}},{"id":2876304,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2021-02-05T16:41:34.000Z","date":"2021-02-04","kind":"sale","acquired":false,"shares":3890,"price":11.21,"value":43606.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on February 3, 2020. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":331977,"source":{"system":"sec-edgar","filing":"0000899243-21-005044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924321005044/doc4.xml","form_type":"4"}},{"id":2884692,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T21:09:20.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":417443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 1, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 417,443 shares of Common Stock, with 25% vesting on February 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":417443,"derivative":{"exercise_price":11.02,"expiration_date":"2031-01-31","underlying":"Common Stock","underlying_shares":417443},"source":{"system":"sec-edgar","filing":"0000899243-21-004523","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924321004523/doc4.xml","form_type":"4"}},{"id":2884691,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2021-02-02T21:09:20.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 87,500 restricted stock units (\"RSUs\") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 1, 2022."}],"balance_after":335867,"source":{"system":"sec-edgar","filing":"0000899243-21-004523","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924321004523/doc4.xml","form_type":"4"}},{"id":2893220,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2021-01-27T20:44:08.000Z","date":"2021-01-25","kind":"sale","acquired":false,"shares":6069,"price":11.41,"value":69247.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on January 24, 2019. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person acquired (i) 708 shares of Common Stock under the Issuer's 2013 Employee Stock Purchase Plan (the \"2013 ESPP\") on August 31, 2018, (ii) 1,120 shares of Common Stock under the 2013 ESPP on February 28, 2019, (iii) 971 shares of Common Stock under the 2013 ESPP on August 31, 2019, and (iv) 996 shares of Common Stock under the 2013 ESPP on February 29, 2020 that were not previously reported on Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person acquired 543 shares of Common Stock under the 2013 ESPP on August 31, 2020."}],"balance_after":248367,"source":{"system":"sec-edgar","filing":"0000899243-21-003535","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924321003535/doc4.xml","form_type":"4"}},{"id":3096322,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-06-30T09:01:28.000Z","date":"2020-06-26","kind":"sale","acquired":false,"shares":4773,"price":16.15,"value":77083.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":250098,"source":{"system":"sec-edgar","filing":"0000899243-20-017904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017904/doc4.xml","form_type":"4"}},{"id":3096321,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-06-30T09:01:28.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":10500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved."}],"balance_after":254871,"source":{"system":"sec-edgar","filing":"0000899243-20-017904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017904/doc4.xml","form_type":"4"}},{"id":3102798,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-22T19:36:57.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":323333,"derivative":{"exercise_price":8.98,"expiration_date":"2026-02-07","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-017444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017444/doc4.xml","form_type":"4"}},{"id":3102797,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-06-22T19:36:57.000Z","date":"2020-06-18","kind":"sale","acquired":false,"shares":10000,"price":22,"value":220000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the sale of shares held by the Reporting Person."}],"balance_after":244371,"source":{"system":"sec-edgar","filing":"0000899243-20-017444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017444/doc4.xml","form_type":"4"}},{"id":3102796,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-06-22T19:36:57.000Z","date":"2020-06-18","kind":"sale","acquired":false,"shares":10000,"price":22,"value":220000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the sale of shares acquired by the Reporting Person upon the exercise of options described in Table II to this Form 4."}],"balance_after":254371,"source":{"system":"sec-edgar","filing":"0000899243-20-017444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017444/doc4.xml","form_type":"4"}},{"id":3102795,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-06-22T19:36:57.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":10000,"price":8.98,"value":89800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":264371,"source":{"system":"sec-edgar","filing":"0000899243-20-017444","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320017444/doc4.xml","form_type":"4"}},{"id":3113281,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T22:19:40.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":23500,"derivative":{"exercise_price":7.31,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001567619-20-012028","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761920012028/doc1.xml","form_type":"4"}},{"id":3159636,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:07:09.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":18500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":4.64,"underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001694187-20-000066","document":"wf-form4_158881361091900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000066/wf-form4_158881361091900.xml","form_type":"4"}},{"id":3159635,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-06T21:07:09.000Z","date":"2020-05-06","kind":"disposition_to_issuer","acquired":false,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 15, 2020, by and among the Issuer, BioNTech SE (\"BioNTech\"), and Endor Lights, Inc. a direct wholly owned subsidiary of BioNTech (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of May 6, 2020 (the \"Effective Time\"), at the Effective Time these options were cancelled for no consideration because these options had an exercise price per Share that was equal to or greater than the product of the volume weighted average price of one BioNTech ADS for the ten trading days immediately prior to the second business day prior to the day of the closing of the Merger, starting with the opening of trading on the first trading day to the closing of the second to last trading day prior to the day of the closing of the Merger, as reported by Bloomberg, multiplied by the Exchange Ratio (the \"Cash Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":7.56,"underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001694187-20-000066","document":"wf-form4_158881361091900.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418720000066/wf-form4_158881361091900.xml","form_type":"4"}},{"id":3194002,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":73409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This stock option was granted on March 24, 2020 under the Company's 2013 Stock Incentive Plan and (i) is vested in full with respect to 44,047 shares, (ii) vests in full on February 8, 2021 with respect to 1,829 shares and (iii) with respect to the remaining 27,533 shares of common stock, vests in seven substantially equal monthly installments, with the first installment vesting on June 24, 2022 and the last installment vesting on December 24, 2022."}],"balance_after":73409,"derivative":{"exercise_price":16.14,"expiration_date":"2030-03-23","underlying":"Common Stock","underlying_shares":73409},"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3194001,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"other","acquired":false,"shares":48727,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The remaining stock options, which were originally granted to Mr. Bazemore on January 24, 2019, are vested with respect to 101,343 shares, with (i) 188,210 of the remaining unvested shares vesting in 26 substantially equal monthly installments from April 24, 2020 through May 24, 2022 (ii) 1,945 of the remaining unvested shares vesting on June 24, 2022 and (iii) 7,239 of  the remaining unvested shares vesting on January 24, 2023."}],"balance_after":298737,"derivative":{"exercise_price":9.12,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":48727},"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3194000,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"other","acquired":false,"shares":2371,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2017, are vested with respect to 258,771 shares, with (i) 69,939 of the remaining unvested shares vesting in ten substantially equal monthly installments from April 8, 2020 through January 8, 2021 and (ii) 4,623 of the remaining shares vesting on February 8, 2021."}],"balance_after":333333,"derivative":{"exercise_price":12.45,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":2371},"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3193999,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"other","acquired":false,"shares":79167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2016, have vested in full."}],"balance_after":333333,"derivative":{"exercise_price":8.98,"expiration_date":"2026-02-07","underlying":"Common Stock","underlying_shares":79167},"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3193998,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-25","kind":"sale","acquired":false,"shares":3285,"price":15.28,"value":50194.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 6. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":254371,"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3193997,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved."}],"balance_after":257656,"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3193996,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":113393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of shares of common stock issuable under restricted stock units granted pursuant to the Company's 2013 Stock Incentive Plan.  Each restricted stock unit represents the right to receive one share of common stock upon vesting.  56,537 of the restricted stock units are scheduled to vest in three equal annual installments on January 24, 2021, January 24, 2022 and January 24, 2023.  The balance of the restricted stock units are scheduled to vest in two equal annual installments over two years from the grant date."}],"balance_after":250656,"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3193995,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-03-26T21:00:29.000Z","date":"2020-03-24","kind":"other","acquired":false,"shares":56537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants."}],"balance_after":80726,"source":{"system":"sec-edgar","filing":"0000899243-20-009605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320009605/doc4.xml","form_type":"4"}},{"id":3288262,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-05T18:10:29.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":252956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 3, 2020 pursuant to the Company's 2013 Stock Incentive Plan with respect to 252,956 shares of Common Stock, with 25% vesting on February 3, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":252956,"derivative":{"exercise_price":21.39,"expiration_date":"2030-02-02","underlying":"Common Stock","underlying_shares":252956},"source":{"system":"sec-edgar","filing":"0000899243-20-003376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320003376/doc4.xml","form_type":"4"}},{"id":3288261,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2020-02-05T18:10:29.000Z","date":"2020-02-03","kind":"grant","acquired":true,"shares":52595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 52,595 restricted stock units (\"RSUs\") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on February 3, 2021."}],"balance_after":137263,"source":{"system":"sec-edgar","filing":"0000899243-20-003376","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320003376/doc4.xml","form_type":"4"}},{"id":3301124,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-01-27T21:17:38.000Z","date":"2020-01-27","kind":"sale","acquired":false,"shares":6074,"price":20.44,"value":124152.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units granted under the issuer's 2013 Stock Incentive Plan on January 24, 2019.  The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":84668,"source":{"system":"sec-edgar","filing":"0000899243-20-002113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320002113/doc4.xml","form_type":"4"}},{"id":3301123,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-01-27T21:17:38.000Z","date":"2020-01-24","kind":"sale","acquired":false,"shares":3002,"price":24.62,"value":73909.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1.  The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":90742,"source":{"system":"sec-edgar","filing":"0000899243-20-002113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320002113/doc4.xml","form_type":"4"}},{"id":3301122,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2020-01-27T21:17:38.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":8750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved."}],"balance_after":93744,"source":{"system":"sec-edgar","filing":"0000899243-20-002113","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924320002113/doc4.xml","form_type":"4"}},{"id":3476916,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-27T08:26:10.000Z","date":"2019-06-25","kind":"grant","acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 25, 2019 with respect to 18,500 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant."}],"balance_after":18500,"derivative":{"exercise_price":4.64,"expiration_date":"2029-06-24","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001694187-19-000048","document":"wf-form4_156163835462992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000169418719000048/wf-form4_156163835462992.xml","form_type":"4"}},{"id":3487630,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-17T20:35:04.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":2.74,"expiration_date":"2029-06-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001567619-19-013484","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000156761919013484/doc1.xml","form_type":"4"}},{"id":3489061,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2019-06-14T18:53:52.000Z","date":"2019-06-13","kind":"sale","acquired":false,"shares":2074,"price":12.1,"value":25095.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 1.  The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person."}],"balance_after":84994,"source":{"system":"sec-edgar","filing":"0000899243-19-017098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924319017098/doc4.xml","form_type":"4"}},{"id":3489060,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock, par value $0.0001","published_at":"2019-06-14T18:53:52.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved."}],"balance_after":87068,"source":{"system":"sec-edgar","filing":"0000899243-19-017098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924319017098/doc4.xml","form_type":"4"}},{"id":3685132,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-28T20:14:38.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":347464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on January 24, 2019 pursuant to the Company's 2013 Stock Incentive Plan with respect to 347,464 shares of Common Stock, with 25% vesting on January 24, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":347464,"derivative":{"exercise_price":9.12,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":347464},"source":{"system":"sec-edgar","filing":"0000899243-19-002089","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924319002089/doc4.xml","form_type":"4"}},{"id":3685131,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2019-01-28T20:14:38.000Z","date":"2019-01-24","kind":"grant","acquired":true,"shares":75383,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 75,383 restricted stock units (\"RSUs\") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in four equal annual installments over four years from the grant date, with the first installment vesting on January 24, 2020."}],"balance_after":80068,"source":{"system":"sec-edgar","filing":"0000899243-19-002089","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000089924319002089/doc4.xml","form_type":"4"}},{"id":3771578,"issuer":{"id":149433,"kind":"organization","name":"Neon Therapeutics, Inc.","symbol":"NTGN"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-11-07T20:02:14.000Z","date":"2018-11-07","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of this option shall vest and become exercisable on November 7, 2019, with the remainder vesting in 24 equal monthly installments thereafter."}],"balance_after":28000,"derivative":{"exercise_price":7.56,"expiration_date":"2028-11-06","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001104659-18-066729","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694187/000110465918066729/a4.xml","form_type":"4"}},{"id":3892488,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-15T22:57:08.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.03,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-18-028862","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036118028862/doc1.xml","form_type":"4"}},{"id":4062084,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-13T17:04:50.000Z","date":"2018-02-09","kind":"grant","acquired":true,"shares":265860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 9, 2018 pursuant to the Company's 2013 Stock Incentive Plan with respect to 265,860 shares of Common Stock, with 25% vesting on February 9, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":265860,"derivative":{"exercise_price":16,"expiration_date":"2028-02-08","underlying":"Common Stock","underlying_shares":265860},"source":{"system":"sec-edgar","filing":"0001209191-18-009631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000120919118009631/doc4.xml","form_type":"4"}},{"id":4286933,"issuer":{"id":4972,"kind":"organization","name":"ARDELYX, INC."},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-09T23:04:13.000Z","date":"2017-06-07","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.3,"expiration_date":"2027-06-07","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-17-024616","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437402/000114036117024616/doc1.xml","form_type":"4"}},{"id":4408244,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common stock, par value $0.0001","published_at":"2017-03-02T16:02:02.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":1708,"price":6.2135,"value":10612.658,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Epizyme, Inc. 2013 Employee Stock Purchase Plan in connection with offering period ended February 28, 2017."}],"balance_after":3070,"source":{"system":"sec-edgar","filing":"0001209191-17-016497","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000120919117016497/doc4.xml","form_type":"4"}},{"id":4459152,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":36784,"kind":"person","name":"Bazemore Robert B","position":1,"cik":"0001620152","reported_name":"Bazemore Robert B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-09T17:59:45.000Z","date":"2017-02-08","kind":"grant","acquired":true,"shares":335704,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 8, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 335,704 shares of Common Stock, with 25% vesting on February 8, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":335704,"derivative":{"exercise_price":12.45,"expiration_date":"2027-02-07","underlying":"Common Stock","underlying_shares":335704},"source":{"system":"sec-edgar","filing":"0001209191-17-009202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1571498/000120919117009202/doc4.xml","form_type":"4"}}]}